A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder-Reference-Cited by-同舟云学术

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

Published:2023-03-24 Issue:4 Volume:37 Page:337-350
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Harlin Matthew^ORCID,Yildirim Murat^ORCID,Such Pedro^ORCID,Madera-McDonough Jessica^ORCID,Jan Michael^ORCID,Jin Na,Watkin Suzanne,Larsen Frank^ORCID

Funder

Otsuka Pharmaceutical Development and Commercialization

H. Lundbeck A/S

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-023-00996-8.pdf

Reference39 articles.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, DC: American Psychiatric Association; 2013.

2. Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59. https://doi.org/10.1007/s40263-020-00779-5.

3. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021. https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841. Accessed 22 Jun 2022.

4. Vázquez GH, Holtzman JN, Lolich M, Ketter TA, Baldessarini RJ. Recurrence rates in bipolar disorder: systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials. Eur Neuropsychopharmacol. 2015;25(10):1501–12. https://doi.org/10.1016/j.euroneuro.2015.07.013.

5. Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2020;34(6):579–98. https://doi.org/10.1007/s40263-020-00713-9.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, 4-year mirror-image study comparing the effectiveness of long- acting injectable antipsychotics in the treatment of Bipolar Disorder: Results from the LAICO study;2024-08-09

2. The new long-acting injectable for maintenance treatment of schizophrenia: What is the clinical value of aripiprazole 2-month ready-to-use 960 mg?;The European Journal of Psychiatry;2024-07

3. Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder;Drugs & Therapy Perspectives;2024-05

4. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder;Clinical Pharmacology in Drug Development;2024-04-11

5. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review;Psychiatry Research;2024-03